Florida Health Sciences Center INC
Florida Health Sciences Center INC was paid $53.21M by Medicaid between Jan 2018 and Dec 2024, across 586 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 11% of everything it billed.
33Billing provider infoFLORIDA HEALTH SCIENCES CENTER INC
TAMPA, FL 33606
TAMPA, FL 33606
33aNPI1235196510assigned 04/28/2006
33bProvider typeWound Care Registered Nurse
28Total paid$53.21M
24GClaims2,306,917
24DCodes billed586
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Wound Care Registered Nurse providers in Florida
Rank by total paid#1 of 15
Median peer was paid$75K
This provider vs. median710×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 155,335 | $2.79M | |
| 2019 | 528,993 | $9.66M | |
| 2020 | 447,698 | $9.58M | |
| 2021 | 491,709 | $11.01M | |
| 2022 | 448,107 | $10.94M | |
| 2023 | 171,131 | $6.19M | |
| 2024incomplete | 63,944 | $3.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 75,024 | 61,984 | $5.72M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.8% | 50,055 | 45,279 | $4.17M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 31,518 | 27,382 | $2.74M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.6% | 45,997 | 39,731 | $2.42M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.4% | 33,607 | 27,205 | $2.33M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.9% | 28,527 | 24,393 | $2.09M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3.7% | 16,014 | 13,776 | $1.95M |
| A0431 | Ambulance service, conventional air services, transport, one way (rotary wing) | 2.7% | 2,299 | 1,824 | $1.43M |
| 80053 | Comprehensive metabolic panel | 2.4% | 117,670 | 84,758 | $1.29M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 8,255 | 7,288 | $1.11M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 13,682 | 12,630 | $1.10M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.6% | 12,471 | 11,168 | $867K |
574 more codes
| 59025 | Fetal non-stress test | 1.5% | 8,745 | $805K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.4% | 21,375 | $745K |
| G0378 | Hospital observation service, per hour | 1.3% | 37,755 | $690K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 12,075 | $681K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 33,449 | $670K |
| 84703 | 1.3% | 29,323 | $666K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 10,827 | $657K |
| J7050 | Infusion, normal saline solution, 250 cc | 1.2% | 12,545 | $651K |
| 81003 | 1.1% | 14,653 | $562K | |
| 96376 | 1.0% | 22,138 | $544K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.0% | 8,827 | $537K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,175 | $480K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 17,688 | $440K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,909 | $427K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 33,286 | $424K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 1,515 | $403K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,346 | $391K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 8,154 | $386K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 8,642 | $386K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 5,973 | $382K |
| 86850 | <1% | 9,747 | $377K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,486 | $369K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 145,472 | $346K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 8,063 | $335K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 11,779 | $328K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 26,759 | $313K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 9,235 | $303K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,554 | $288K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 744 | $278K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 13,558 | $277K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,393 | $268K |
| 77336 | <1% | 755 | $260K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 74 | $256K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,833 | $256K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,275 | $246K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 23,685 | $221K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 973 | $220K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 7,404 | $212K |
| 96415 | <1% | 4,057 | $206K | |
| A0436 | Rotary wing air mileage, per statute mile | <1% | 2,257 | $201K |
| 36416 | <1% | 3,133 | $190K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,398 | $186K |
| 92551 | <1% | 5,163 | $183K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,752 | $168K |
| 81001 | <1% | 58,553 | $163K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30,946 | $160K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 2,884 | $159K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 25,063 | $156K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,989 | $155K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,250 | $148K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14,998 | $143K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 292 | $140K |
| 85610 | <1% | 20,257 | $131K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,537 | $121K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 23,095 | $119K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 26,191 | $116K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,960 | $114K |
| 87631 | <1% | 4,777 | $114K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,194 | $113K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13,354 | $112K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 21,489 | $104K |
| 77386 | <1% | 687 | $102K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,840 | $100K |
| 00731 | <1% | 1,589 | $99K | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 765 | $96K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,529 | $95K |
| 96367 | <1% | 3,899 | $93K | |
| 36430 | <1% | 1,240 | $91K | |
| 97162 | <1% | 2,747 | $91K | |
| 76801 | <1% | 1,239 | $87K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,130 | $87K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 16,221 | $83K |
| 83735 | <1% | 26,598 | $80K | |
| 76820 | <1% | 2,506 | $80K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,673 | $79K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,165 | $78K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,493 | $74K |
| 47562 | <1% | 42 | $71K | |
| 85018 | <1% | 7,379 | $68K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,170 | $65K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,544 | $65K |
| 84702 | <1% | 6,089 | $62K | |
| 86900 | <1% | 11,117 | $61K | |
| C1769 | Guide wire | <1% | 3,880 | $60K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 4,912 | $59K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 3,592 | $57K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 603 | $56K |
| J2704 | Injection, propofol, 10 mg | <1% | 19,600 | $54K |
| 70496 | <1% | 438 | $52K | |
| 94760 | <1% | 5,723 | $52K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,691 | $51K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 29,643 | $50K |
| 85730 | <1% | 9,586 | $50K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 9,251 | $49K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 834 | $48K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,744 | $48K |
| 85384 | <1% | 887 | $47K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,362 | $46K |
| 49083 | <1% | 734 | $46K | |
| 86901 | <1% | 11,619 | $45K | |
| 92523 | <1% | 565 | $44K | |
| 73130 | <1% | 2,335 | $43K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,619 | $43K |
| 82330 | <1% | 8,273 | $43K | |
| 97161 | <1% | 1,445 | $43K | |
| 76825 | <1% | 656 | $42K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,196 | $42K |
| 84156 | <1% | 9,832 | $41K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,469 | $41K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 9,071 | $41K |
| 76830 | Ultrasound, transvaginal | <1% | 2,776 | $41K |
| 95714 | <1% | 189 | $39K | |
| 93970 | <1% | 1,858 | $38K | |
| J0485 | Injection, belatacept, 1 mg | <1% | 700 | $38K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 2,490 | $38K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,647 | $37K |
| 82947 | <1% | 7,806 | $37K | |
| 84132 | <1% | 6,195 | $36K | |
| 90647 | <1% | 6,969 | $36K | |
| 84295 | <1% | 5,774 | $35K | |
| 75572 | <1% | 1,223 | $35K | |
| 71045 | Radiologic examination, chest; single view | <1% | 18,001 | $35K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 699 | $34K |
| 73610 | <1% | 2,215 | $34K | |
| 87077 | <1% | 3,902 | $34K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 743 | $33K |
| 89051 | <1% | 1,368 | $33K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,882 | $32K |
| 70498 | <1% | 377 | $32K | |
| 95806 | <1% | 607 | $32K | |
| 94010 | <1% | 1,853 | $31K | |
| 80197 | <1% | 14,685 | $31K | |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 2,761 | $30K |
| 87210 | <1% | 6,736 | $30K | |
| 82435 | <1% | 5,202 | $30K | |
| 84484 | <1% | 22,573 | $29K | |
| 70486 | <1% | 595 | $29K | |
| 96417 | <1% | 1,867 | $28K | |
| 73110 | <1% | 1,692 | $28K | |
| 94664 | <1% | 323 | $28K | |
| 76775 | <1% | 1,247 | $27K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,995 | $27K |
| 97116 | <1% | 3,270 | $27K | |
| 99201 | <1% | 672 | $27K | |
| 73564 | <1% | 2,763 | $27K | |
| 00813 | <1% | 181 | $27K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,415 | $26K |
| 97166 | <1% | 853 | $25K | |
| 93971 | <1% | 2,042 | $25K | |
| 87070 | <1% | 3,356 | $25K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,821 | $25K |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | <1% | 93 | $25K |
| 83880 | <1% | 11,621 | $24K | |
| 71250 | <1% | 824 | $24K | |
| 93975 | <1% | 1,600 | $24K | |
| 74018 | <1% | 2,179 | $23K | |
| 93797 | <1% | 706 | $23K | |
| 97163 | <1% | 362 | $23K | |
| 73630 | <1% | 2,292 | $22K | |
| 82570 | <1% | 14,068 | $22K | |
| 10060 | <1% | 378 | $22K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,174 | $22K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,187 | $22K |
| 93017 | <1% | 1,900 | $22K | |
| 00840 | <1% | 956 | $22K | |
| J1815 | Injection, insulin, per 5 units | <1% | 8,091 | $22K |
| 99205 | Prolong outpt/office vis | <1% | 801 | $21K |
| 73090 | <1% | 1,327 | $21K | |
| 76000 | <1% | 1,475 | $21K | |
| 70491 | <1% | 285 | $21K | |
| 77301 | <1% | 13 | $20K | |
| 88342 | <1% | 2,223 | $20K | |
| 94060 | <1% | 495 | $20K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 2,042 | $20K |
| 88307 | <1% | 1,399 | $19K | |
| 92526 | <1% | 546 | $19K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,830 | $19K |
| 82803 | <1% | 8,541 | $19K | |
| 00400 | <1% | 622 | $19K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,476 | $19K |
| 80061 | Lipid panel | <1% | 8,962 | $19K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 48 | $19K |
| 83605 | <1% | 12,268 | $18K | |
| 95811 | <1% | 79 | $18K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 779 | $18K |
| 99188 | <1% | 2,874 | $18K | |
| 73080 | <1% | 1,023 | $18K | |
| 81025 | <1% | 9,332 | $18K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,513 | $17K |
| 12011 | <1% | 187 | $17K | |
| 00300 | <1% | 281 | $17K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 4,490 | $16K |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 626 | $16K |
| 16020 | <1% | 942 | $15K | |
| 87186 | <1% | 4,082 | $15K | |
| 94660 | <1% | 690 | $15K | |
| 88720 | <1% | 359 | $15K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 860 | $14K |
| 73030 | <1% | 1,809 | $14K | |
| 73590 | <1% | 1,292 | $14K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,141 | $14K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 441 | $14K |
| 82728 | <1% | 5,099 | $14K | |
| 73552 | <1% | 971 | $14K | |
| 83690 | <1% | 19,187 | $14K | |
| 90686 | <1% | 13,599 | $13K | |
| 88304 | <1% | 1,170 | $13K | |
| 92651 | <1% | 383 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 700 | $13K |
| 82105 | <1% | 1,129 | $13K | |
| 80321 | <1% | 4,124 | $12K | |
| 86304 | <1% | 1,087 | $12K | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 305 | $12K |
| 86803 | <1% | 10,762 | $12K | |
| 95819 | <1% | 221 | $12K | |
| 19318 | <1% | 12 | $12K | |
| 87641 | <1% | 3,411 | $12K | |
| 01922 | <1% | 103 | $11K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 362 | $11K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 5,339 | $11K |
| 85046 | <1% | 3,687 | $11K | |
| 82607 | <1% | 3,752 | $11K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 3,939 | $11K |
| 87340 | <1% | 3,593 | $11K | |
| 82805 | <1% | 3,595 | $11K | |
| 80051 | <1% | 4,762 | $11K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 4,015 | $10K |
| 87497 | <1% | 3,440 | $10K | |
| 82550 | <1% | 5,771 | $10K | |
| 12001 | <1% | 153 | $10K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,251 | $10K |
| 85660 | <1% | 613 | $10K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 13,423 | $10K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 137 | $10K |
| 94729 | <1% | 1,171 | $10K | |
| 93325 | <1% | 907 | $10K | |
| 74022 | <1% | 961 | $9K | |
| 86706 | <1% | 2,162 | $9K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13,634 | $9K |
| 92567 | <1% | 155 | $9K | |
| 83540 | <1% | 4,020 | $9K | |
| 84100 | <1% | 7,514 | $9K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,075 | $9K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 9,991 | $9K |
| 87653 | <1% | 981 | $9K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 115 | $9K |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 106 | $8K |
| 86704 | <1% | 1,917 | $8K | |
| 72110 | <1% | 1,364 | $8K | |
| 86352 | <1% | 612 | $8K | |
| 92586 | <1% | 188 | $8K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,930 | $8K |
| 87205 | <1% | 2,968 | $8K | |
| 88142 | <1% | 567 | $8K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 2,981 | $8K |
| 43235 | <1% | 163 | $8K | |
| 80069 | <1% | 989 | $8K | |
| 73502 | <1% | 1,746 | $8K | |
| 77300 | <1% | 45 | $8K | |
| 83550 | <1% | 3,693 | $8K | |
| 74019 | <1% | 351 | $7K | |
| 90715 | <1% | 5,926 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 9,053 | $7K |
| 87536 | <1% | 472 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 273 | $7K |
| 84439 | <1% | 3,260 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 37,025 | $7K |
| 76604 | <1% | 309 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 289 | $7K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 425 | $7K |
| A4690 | Dialyzer (artificial kidneys), all types, all sizes, for hemodialysis, each | <1% | 2,150 | $7K |
| A4570 | Splint | <1% | 270 | $7K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 940 | $7K |
| 00790 | <1% | 80 | $7K | |
| 88341 | <1% | 1,024 | $7K | |
| 96368 | <1% | 603 | $7K | |
| 85014 | <1% | 1,271 | $7K | |
| 82746 | <1% | 3,441 | $7K | |
| 90670 | <1% | 8,814 | $6K | |
| 86708 | <1% | 2,586 | $6K | |
| 97165 | <1% | 209 | $6K | |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | <1% | 2,136 | $6K |
| 86141 | <1% | 6,071 | $6K | |
| 90633 | <1% | 2,790 | $6K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 374 | $6K |
| 96416 | <1% | 206 | $6K | |
| 86923 | <1% | 1,338 | $6K | |
| 88300 | <1% | 1,143 | $6K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 128 | $6K |
| 87799 | <1% | 1,193 | $6K | |
| 92610 | <1% | 176 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,682 | $6K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 478 | $6K |
| 85652 | <1% | 4,132 | $5K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 484 | $5K |
| 85379 | <1% | 3,877 | $5K | |
| 73060 | <1% | 466 | $5K | |
| P9041 | Infusion, albumin (human), 5%, 50 ml | <1% | 34 | $5K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 89 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 620 | $5K |
| 76857 | <1% | 2,025 | $5K | |
| 94618 | <1% | 204 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 998 | $5K |
| 87040 | <1% | 2,986 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,306 | $5K |
| 90651 | <1% | 1,294 | $5K | |
| 86592 | <1% | 716 | $5K | |
| 87507 | <1% | 352 | $5K | |
| 83615 | <1% | 2,303 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,650 | $5K |
| 77001 | <1% | 413 | $5K | |
| 93350 | <1% | 61 | $4K | |
| 82375 | <1% | 1,159 | $4K | |
| 82553 | <1% | 2,534 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 169 | $4K |
| 58661 | <1% | 27 | $4K | |
| 84550 | <1% | 1,147 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 215 | $4K |
| 82043 | <1% | 2,919 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,254 | $4K |
| 00142 | <1% | 168 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 174 | $4K |
| 86807 | <1% | 513 | $4K | |
| 96401 | <1% | 168 | $4K | |
| 83970 | <1% | 1,529 | $4K | |
| 86021 | <1% | 482 | $4K | |
| 74183 | <1% | 81 | $4K | |
| 91300 | <1% | 405 | $4K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 205 | $3K |
| 92588 | <1% | 446 | $3K | |
| 87015 | <1% | 212 | $3K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 227 | $3K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,552 | $3K |
| 29705 | <1% | 183 | $3K | |
| 86644 | <1% | 1,527 | $3K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,669 | $3K |
| J0248 | Injection, remdesivir, 1 mg | <1% | 28 | $3K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 965 | $3K |
| 76821 | <1% | 174 | $3K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 112 | $3K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 30 | $3K |
| 76642 | <1% | 102 | $3K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 273 | $3K |
| 36591 | <1% | 754 | $3K | |
| 93880 | <1% | 127 | $3K | |
| 80329 | <1% | 1,592 | $2K | |
| 72100 | <1% | 345 | $2K | |
| 72146 | <1% | 15 | $2K | |
| 51798 | <1% | 1,548 | $2K | |
| 72170 | <1% | 955 | $2K | |
| 86480 | <1% | 1,010 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,364 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,587 | $2K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 25 | $2K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,945 | $2K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 21 | $2K |
| 93451 | <1% | 18 | $2K | |
| 94726 | <1% | 775 | $2K | |
| H2019 | Therapeutic behavioral services, billed per 15 minutes | <1% | 55 | $2K |
| 82150 | <1% | 991 | $2K | |
| 84460 | <1% | 141 | $2K | |
| 86945 | <1% | 258 | $2K | |
| 82378 | <1% | 414 | $2K | |
| 93922 | <1% | 172 | $2K | |
| 76827 | <1% | 660 | $2K | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 194 | $2K |
| 95700 | <1% | 142 | $2K | |
| 90696 | <1% | 1,080 | $2K | |
| 84145 | <1% | 1,165 | $2K | |
| 93458 | <1% | 12 | $2K | |
| 85347 | <1% | 54 | $2K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 351 | $1K |
| 80076 | <1% | 521 | $1K | |
| 72072 | <1% | 151 | $1K | |
| 88184 | <1% | 263 | $1K | |
| 85027 | <1% | 404 | $1K | |
| 82977 | <1% | 1,000 | $1K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 14 | $1K |
| 82784 | <1% | 262 | $1K | |
| 86762 | <1% | 682 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,650 | $1K |
| 72141 | <1% | 93 | $1K | |
| 90837 | Psychotherapy session, about an hour | <1% | 75 | $1K |
| 86038 | <1% | 368 | $1K | |
| 97542 | <1% | 18 | $1K | |
| 29125 | <1% | 340 | $1K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 18 | $1K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 319 | $1K |
| 70100 | <1% | 530 | $1K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 12 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,055 | $1K |
| 87102 | <1% | 377 | $1K | |
| 0002A | <1% | 173 | $1K | |
| 86682 | <1% | 690 | $992.83 | |
| 96156 | <1% | 67 | $986.74 | |
| 84480 | <1% | 944 | $982.96 | |
| 82950 | <1% | 92 | $975.07 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 177 | $960.83 |
| 72192 | <1% | 16 | $892.29 | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 181 | $889.84 |
| 90723 | <1% | 7,345 | $881.92 | |
| H2000 | Comprehensive multidisciplinary evaluation | <1% | 20 | $878.69 |
| 86790 | <1% | 771 | $850.21 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,072 | $842.33 |
| 93016 | <1% | 430 | $842.15 | |
| 82565 | <1% | 312 | $837.52 | |
| 73140 | <1% | 62 | $822.29 | |
| 87529 | <1% | 148 | $816.90 | |
| 86832 | <1% | 274 | $796.56 | |
| V2632 | Posterior chamber intraocular lens | <1% | 106 | $779.70 |
| 76870 | <1% | 127 | $774.36 | |
| G0008 | Administration of influenza virus vaccine | <1% | 936 | $762.15 |
| 86780 | <1% | 224 | $758.71 | |
| 86695 | <1% | 722 | $753.79 | |
| 84436 | <1% | 713 | $753.71 | |
| 99173 | <1% | 5,479 | $727.41 | |
| 71101 | <1% | 46 | $718.56 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 389 | $715.17 |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 18 | $704.68 |
| 87116 | <1% | 216 | $686.88 | |
| 76813 | <1% | 117 | $683.62 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 293 | $663.49 |
| 86787 | <1% | 718 | $642.31 | |
| 88112 | <1% | 110 | $601.96 | |
| 90734 | <1% | 704 | $585.33 | |
| 86735 | <1% | 644 | $569.20 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 38 | $552.02 |
| 78582 | <1% | 27 | $550.43 | |
| 86777 | <1% | 685 | $549.06 | |
| 86665 | <1% | 756 | $548.88 | |
| 84481 | <1% | 174 | $547.18 | |
| 84153 | <1% | 135 | $546.72 | |
| 86765 | <1% | 639 | $537.30 | |
| 0001A | <1% | 114 | $520.10 | |
| J3471 | Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) | <1% | 131 | $500.50 |
| 90707 | <1% | 1,115 | $496.75 | |
| 87807 | <1% | 16 | $494.09 | |
| 88313 | <1% | 400 | $491.36 | |
| 86308 | <1% | 235 | $488.74 | |
| 90662 | <1% | 404 | $487.26 | |
| 70544 | <1% | 13 | $482.91 | |
| 86905 | <1% | 87 | $464.08 | |
| 84520 | <1% | 259 | $455.51 | |
| 99499 | <1% | 1,163 | $440.02 | |
| 80074 | <1% | 171 | $438.68 | |
| 87808 | <1% | 568 | $423.28 | |
| 82465 | <1% | 616 | $422.22 | |
| 90716 | <1% | 1,044 | $415.42 | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 72 | $410.90 |
| 87517 | <1% | 201 | $402.73 | |
| 87206 | <1% | 115 | $391.64 | |
| 73620 | <1% | 17 | $390.49 | |
| 99251 | <1% | 26 | $383.47 | |
| 94799 | <1% | 206 | $380.56 | |
| 90746 | <1% | 68 | $372.54 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 965 | $369.88 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 14 | $359.60 |
| 82010 | <1% | 1,008 | $352.26 | |
| 90681 | <1% | 5,037 | $344.22 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 97 | $342.33 |
| 64415 | <1% | 51 | $341.97 | |
| J3473 | Injection, hyaluronidase, recombinant, 1 usp unit | <1% | 107 | $335.53 |
| 11721 | <1% | 27 | $323.64 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 95 | $285.48 |
| 87088 | <1% | 342 | $257.39 | |
| 87147 | <1% | 91 | $246.77 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 472 | $239.90 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 896 | $235.95 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 720 | $230.00 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 270 | $222.29 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 91 | $220.26 |
| 87184 | <1% | 158 | $216.07 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 31 | $214.00 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,191 | $208.75 |
| C1729 | Catheter, drainage | <1% | 54 | $208.05 |
| L0172 | Cervical, collar, semi-rigid thermoplastic foam, two-piece, prefabricated, off-the-shelf | <1% | 36 | $197.40 |
| 74150 | <1% | 13 | $188.13 | |
| 72040 | <1% | 49 | $184.95 | |
| Q3014 | Telehealth originating site facility fee | <1% | 505 | $173.89 |
| 90732 | <1% | 163 | $167.24 | |
| 82140 | <1% | 266 | $148.61 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 614 | $136.08 |
| 86361 | <1% | 30 | $135.44 | |
| 77338 | <1% | 13 | $127.54 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $125.05 |
| 80164 | <1% | 51 | $122.18 | |
| 85651 | <1% | 367 | $120.42 | |
| 72131 | <1% | 16 | $117.72 | |
| 94761 | <1% | 38 | $110.76 | |
| 83050 | <1% | 191 | $107.75 | |
| 84311 | <1% | 190 | $107.63 | |
| 87181 | <1% | 62 | $106.89 | |
| 87075 | <1% | 34 | $104.64 | |
| 92611 | <1% | 14 | $101.71 | |
| 93925 | <1% | 52 | $93.88 | |
| 83520 | <1% | 15 | $92.19 | |
| 85007 | <1% | 146 | $88.30 | |
| 83516 | <1% | 13 | $84.76 | |
| 86593 | <1% | 115 | $84.05 | |
| 83020 | <1% | 174 | $83.85 | |
| 86769 | <1% | 116 | $79.46 | |
| 0053A | <1% | 98 | $77.00 | |
| 86300 | <1% | 20 | $69.11 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 134 | $62.52 |
| 84160 | <1% | 75 | $49.99 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 12 | $49.89 |
| 90700 | <1% | 2,026 | $45.85 | |
| 85576 | <1% | 17 | $45.48 | |
| 94762 | <1% | 36 | $44.40 | |
| 36600 | <1% | 80 | $44.30 | |
| 86870 | <1% | 30 | $42.81 | |
| 84165 | <1% | 51 | $42.08 | |
| 73560 | <1% | 46 | $36.77 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 168 | $32.78 |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 84 | $32.37 |
| 00910 | <1% | 42 | $25.45 | |
| 87081 | <1% | 33 | $21.73 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 25 | $20.12 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 63 | $17.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 30 | $16.60 |
| 90694 | <1% | 119 | $16.50 | |
| A9558 | Xenon xe-133 gas, diagnostic, per 10 millicuries | <1% | 27 | $10.36 |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | <1% | 27 | $10.36 |
| 84157 | <1% | 25 | $9.96 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 73 | $9.66 |
| A6512 | Compression burn garment, not otherwise classified | <1% | 12 | $9.15 |
| 00902 | <1% | 28 | $6.64 | |
| C1781 | Mesh (implantable) | <1% | 46 | $6.64 |
| 82945 | <1% | 20 | $6.64 | |
| 82247 | <1% | 31 | $5.55 | |
| 00812 | <1% | 14 | $3.32 | |
| 1036F | 0% | 84 | $0.00 | |
| 90620 | 0% | 14 | $0.00 | |
| 82533 | 0% | 12 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 67 | $0.00 |
| 83883 | 0% | 19 | $0.00 | |
| 90677 | 0% | 68 | $0.00 | |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | 0% | 91 | $0.00 |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 53 | $0.00 |
| 0011A | 0% | 13 | $0.00 | |
| 36902 | 0% | 19 | $0.00 | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 0% | 78 | $0.00 |
| 97802 | 0% | 16 | $0.00 | |
| 00320 | 0% | 21 | $0.00 | |
| 88331 | 0% | 17 | $0.00 | |
| 96409 | 0% | 23 | $0.00 | |
| 97804 | 0% | 46 | $0.00 | |
| 83051 | 0% | 17 | $0.00 | |
| 3017F | 0% | 15 | $0.00 | |
| 86255 | 0% | 12 | $0.00 | |
| 86702 | 0% | 14 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 16 | $0.00 |
| 86701 | 0% | 14 | $0.00 | |
| 82248 | 0% | 49 | $0.00 | |
| 83721 | 0% | 16 | $0.00 | |
| 90713 | 0% | 489 | $0.00 | |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 46 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 376 | $0.00 |
| 90710 | 0% | 1,085 | $0.00 | |
| 00402 | 0% | 12 | $0.00 | |
| 0003A | 0% | 207 | $0.00 | |
| 80305 | 0% | 18 | $0.00 | |
| 0124A | 0% | 15 | $0.00 | |
| 88302 | 0% | 101 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 24 | $0.00 |
| 0013A | 0% | 40 | $0.00 | |
| 01830 | 0% | 12 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 48 | $0.00 |
| 69210 | 0% | 12 | $0.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 54 | $0.00 |
| 0479T | 0% | 59 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 16 | $0.00 |
| 80195 | 0% | 15 | $0.00 | |
| 88344 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOURIS, JOHN (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Jupiter Medical Center, INC. | Jupiter, FL | $4.70M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.